Aceragen announces dosing of first patient with ACG-701 in clinical trial for…
RALEIGH-DURHAM, NC , June 15, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high…